指南与共识卫生政策与健康促进免疫规划

欧盟27国与英国疫苗市场准入路径的分析与改进建议

Vaccine market access pathways in the EU27 and the United Kingdom - analysis and recommendations for improvements.
指南 / 共识 · Vaccine · 2021-08-14

该研究分两阶段评估欧盟与英国疫苗市场准入路径:基于文献综述、专家访谈和数学原型法绘制各成员国路径,并通过疫苗专家访谈识别障碍、驱动因素与区域对齐建议。结果显示准入步骤复杂异质,NITAG与HTA角色及透明度差异显著,快速准入的关键驱动为疾病负担与疫苗效益展示,主要障碍为预算限制与流程复杂性。

要点

  • 欧盟疫苗市场准入含 horizon scanning、早期建议、NITAG推荐、HTA、最终决策与采购等关键步骤。
  • 快速准入最重要驱动为展示疾病负担与疫苗效益(效价、安全性、经济性)。
  • 主要障碍为预算限制及准入流程复杂性与清晰度不足。

核心结论

  • 欧盟疫苗市场准入存在显著对齐、协作与改进潜力,关键机构角色、职责与透明度可进一步明确。
  • COVID-19大流行应对应推动改善所有疫苗(包括常规疫苗)可及性的政策,并奠定建立一致疫苗生态系统的基础。

研究设计与样本

  • 研究分两阶段:第一阶段基于文献综述、专家访谈和数学原型法绘制每个欧盟成员国(含英国)的疫苗市场准入路径。
  • 第二阶段通过与疫苗专家访谈识别障碍、驱动因素及区域疫苗市场准入对齐建议。

主要发现

  • 欧盟疫苗市场准入关键步骤包括 horizon scanning、早期建议、国家免疫技术咨询组(NITAG)推荐纳入国家免疫规划、卫生技术评估(HTA)、最终决策与采购。
  • 在早期建议方面,以及NITAG与HTA机构的角色、决策标准和透明度方面,存在显著复杂性与异质性。
  • 快速疫苗市场准入的最重要驱动因素包括展示疾病负担和疫苗效益(如效价、安全性、经济性)。
  • 关键障碍为预算限制和疫苗市场准入流程的复杂性/清晰度不足(如需要国家-区域共识、流程启动清晰度、HTA角色清晰度)。

关键数值与推荐

  • 欧盟与成员国层面的对齐建议包括信息共享、联合临床评估、解决资金与政治障碍的举措以及提高决策机构透明度。
  • 对生产商的关键建议是尽早与疫苗利益相关方接触。

临床怎么用

  • 决策机构可参考建议明确关键机构的角色、职责与透明度,以简化疫苗市场准入流程。
  • 生产商应尽早与疫苗利益相关方接触,并准备展示疾病负担与疫苗效益证据以促进快速准入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccine market access (VMA) pathways across the European Union (EU) and the United Kingdom (UK) are complex, lengthy, and heterogeneous, particularly when compared with pharmaceuticals. The knowledge base to inform recommendations for optimization of VMA is lacking. We therefore conducted a comprehensive evaluation of EU VMA pathways. METHODS: Research in two phases included: (1) mapping VMA pathways in each EU member state (including the UK) based on a literature review, expert interviews, and mathematical archetyping; and (2) interviews with vaccine experts to identify barriers, drivers, and recommendations for regional VMA alignments. RESULTS: Key steps in VMA across the EU include horizon scanning, early advice, National Immunization Technical Advisory Group (NITAG) recommendation for inclusion in national immunization programs, health technology assessment (HTA), final decision and procurement. We found significant complexity and heterogeneity, particularly for early advice, and in the roles, decision-making criteria, and transparency of NITAGs and HTA bodies. The most important drivers for rapid VMA included demonstration of disease burden and vaccine benefit (e.g., efficacy, safety, economic). Key barriers were budget limitations and complexity/clarity of VMA processes (e.g., need for national-regional consensus, clarity on process initiation, and clarity on the role of HTA). Recommendations for alignment at EU and member-state levels include information sharing, joint clinical assessment, initiatives to address funding and political barriers, and improved transparency by decision-making bodies. Early engagement with vaccine stakeholders was a key recommendation for manufacturers. CONCLUSIONS: There is significant potential for alignment, collaboration, and improvement of VMA across the EU. Roles, responsibilities, and transparency of key bodies can be clarified. The COVID-19 pandemic response should stimulate policies to improve access to all vaccines, including routine ones, and form the foundation upon which a consistent vaccine ecosystem can be created for the EU, one that is resilient, consistent between member states, and fit for purpose.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Laigle V, Postma MJ, Pavlovic M, et al. Vaccine market access pathways in the EU27 and the United Kingdom - analysis and recommendations for improvements. Vaccine. 2021. PMID: 34404557. doi:10.1016/j.vaccine.2021.07.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。